A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

Hyperammonemia Clinical Trial

Official title:
A Phase 1, Randomised, Open-Label, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of PBI-4050 Compared to Sodium Phenylbutyrate in Healthy Subjects

Status Terminated

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products are given as single ascending doses to healthy adult subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hyperammonemia

Clinical Trial Details

NCT number	NCT05349435
Study type	Interventional
Source	Liminal BioSciences Ltd.
Contact
Status	Terminated
Phase	Phase 1
Start date	May 13, 2022
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05842837` - A Non-Interventional Post-Authorization Study of Carbaglu for the Treatment of Hyperammonemia Due to MMA and PA
Completed	`NCT03947034` - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Completed	`NCT06178718` - A Phase 1, Single-center, Double-blind, Placebo-controlled Study of TNP-2092 Capsules, and the Food Effect Study After Single-dose Oral Administration of TNP-2092 Capsules	Phase 1
Recruiting	`NCT05040178` - An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
Withdrawn	`NCT00279851` - Blood Sugars in Children With Idiopathic Seizures.
Completed	`NCT06135675` - Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia	Phase 1/Phase 2